Pseudoprogression Shown on 18F-FDG PET/CT After Pembrolizumab Treatment in a Case of Metastatic Bladder Cancer
A 57-year-old man diagnosed with a metastatic bladder tumor was initiated on pembrolizumab treatment. <sup>18</sup>F-fluorodeoxyglucose (<sup>18</sup>F-FDG) positron emission tomography/computed tomography (PET/CT) imaging performed to evaluate treatment response showed numerical-dimensional and metabolic increase in the metastatic lesions. In the <sup>18</sup>F-FDG PET/CT imaging performed 8 weeks later due to suspicion of pseudoprogression, a significant regression of the lesions was observed, and the patient was diagnosed with pseudoprogression. Pseudoprogression should be kept in mind when <sup>18</sup>F-FDG PET/CT is performed after the use of immunotherapy, and evaluation with follow-up PET/CT is recommended to confirm that the patient has hyperprogression or pseudoprogression.
Authors
- Cihan Gündoğan (ORCID: https://orcid.org/0000-0001-5700-6292)
- Halil Kömek (ORCID: https://orcid.org/0000-0001-8168-136X)
- Veysi Şenses (ORCID: https://orcid.org/0009-0002-0529-9278)
- Fulya Kaya İpek (ORCID: https://orcid.org/0009-0005-4303-4993)
- İbrahim Hakkı Dursun (ORCID: https://orcid.org/0009-0004-3453-194X)
Institutions
- Sağlık Bilimleri Üniversitesi (TR)
- Turkish Society of Cardiology (TR)
- University of Health Sciences Antigua (AG)
Publication Details
- Journal
- Molecular Imaging and Radionuclide Therapy
- Published
- 2024-09-06
- DOI
- https://doi.org/10.4274/mirt.galenos.2024.47135
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.28